News & Press Releases

Mintz is advising the placement agents in connection with the $350 million private placement that is expected to close immediately prior to the completion of the merger transaction between Obsidian Therapeutics, Inc. and Galera Therapeutics, Inc.

Mintz advised the placement agent in connection with ImageneBio’s $30 million private placement of pre-funded warrants.

Mintz advised the placement agent in connection with SCYNEXIS’ up to $92.2 million private placement. The private placement included upfront gross proceeds of approximately $40.0 million in common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants, and up to an additional $52.2 million in gross proceeds if the common warrants are exercised for cash, subject to stockholder approval to increase the number of authorized shares of common stock.

Mintz has again been recognized as one of the most active and high-performing law firms for patent prosecution in Patexia’s LexDana 2026 Patent Prosecution Intelligence Report, reflecting the depth and breadth of the firm’s patent prosecution practice across biotechnology, high‑tech, and other innovation‑driven technologies.

Mintz represented Synnovation Therapeutics LLC, a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology, in connection with its definitive agreement with Novartis to acquire Synnovation’s wholly-owned subsidiary, Pikavation Therapeutics Inc., and its portfolio of pan mutant selective PI3Kα inhibitor programs, including its lead clinical asset SNV4818.  

Mintz advised the underwriters in connection with SAB Biotherapeutics’ $85 million public offering.